RA0115

antibody from Oursmab

Targeting: CD40LG CD154, CD40L, gp39, hCD40L, HIGM1, IMD3, TNFSF5, TRAP

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0115

Provider

Oursmab

Product name

Frexalimab (Biosimilar Reference Antibody) (CD40LG)

Antibody type

Monoclonal

Description

Frexalimab (development code SAR-441344) is an investigational, humanized monoclonal IgG4 antibody being developed for the treatment of autoimmune diseases, with a primary focus on relapsing multiple sclerosis (MS). It represents a novel therapeutic approach by targeting a key component of the immune synapse. Frexalimab functions as a CD40L (CD154) inhibitor. By binding with high affinity to CD40L (also known as CD154) on the surface of activated T cells, it blocks the interaction between CD40L and its receptor CD40 on antigen-presenting cells (e.g., B cells, macrophages, dendritic cells). This blockade inhibits a critical co-stimulatory signal required for full T-cell activation, B-cell differentiation, and antibody class switching, thereby dampening the adaptive immune response thought to drive inflammation in diseases like MS.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.